Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 29
Semaglutide safety in dialysis patients
A 2026 Diabetes Care exchange scrutinised pooled trial data on semaglutide safety after dialysis initiation. What the numbers show and what remains open.
Tirzepatide vs semaglutide: the CV gap
Ostrominski et al. found tirzepatide cuts MACE vs dulaglutide but not vs semaglutide. A 2026 comment asked if active-comparator designs conceal real gains.
Can you freeze a reconstituted peptide?
A reader paused a CJC-1295/ipamorelin cycle and wanted to freeze the rest. Here is what the closest approved label and the freeze-thaw literature say.
Selank and Semax: Should You Combine Them?
Selank has real generalized anxiety disorder trial data. Semax's focus reputation does not, and no study has combined the two.
Tirzepatide vs Semaglutide: Liver Risk
A large real-world study found tirzepatide and injectable semaglutide carry the same risk of serious liver outcomes in adults with type 2 diabetes.
Switching to Tirzepatide: Liver Fibrosis
A Japanese study found switching from other GLP-1 drugs to tirzepatide reduced FIB-4 liver fibrosis scores in high-risk patients.
Avexitide: the GLP-1 drug that blocks it
Avexitide, Amylyx's investigational GLP-1 receptor blocker, cut severe post-bariatric hypoglycemia events by 55 percent in a phase 3 trial.
CagriSema meta-analysis: what it found
Seven pooled CagriSema trials show more weight loss than semaglutide or cagrilintide alone. The combination is still unapproved, and pooled data has limits.
ENV-308: a pill built to mimic exercise
Enveda's ENV-308 mimics an exercise-linked metabolite and aims to preserve muscle after GLP-1 weight loss, but its Phase 1 trial tested only safety.
GLP-1 Drugs and Ankle Osteoarthritis Care
A 2026 cohort study ties GLP-1 receptor agonist use to fewer ankle injections and replacements, but more arthroscopy in diabetes.
GLP-1 drugs and ankle OA: new cohort data
A Johns Hopkins cohort study found obese GLP-1 users had lower rates of ankle injection and arthroplasty. Diabetic users showed higher arthroscopy rates.
Hunger pain: semaglutide in schizophrenia
A qualitative study asked people with schizophrenia how semaglutide changed the hunger antipsychotics can cause.